Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Painful Diabetic Neuropathy
Diabetic Neuropathy, Painful

Interventions

GENETIC: Long-Term Follow-Up of Patients who Received Engensis (VM202)
DRUG: Long-Term Follow-Up of Patients who Received Placebo

Sponsor

Helixmith Co., Ltd.